These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Chemonucleolysis: a note of caution.
    Author: Watts C, Dickhaus E.
    Journal: Surg Neurol; 1986 Sep; 26(3):236-40. PubMed ID: 3738716.
    Abstract:
    Following the approval in 1982 by the Federal Food and Drug Administration of chymopapain for public use by the medical profession in the treatment of ruptured lumbar intervertebral disk disease, chemonucleolysis has become widespread in the United States; a considerable experience has been obtained in the past 3 years, allowing for an appropriate examination of the original claims for the procedure. Chemonucleolysis is not as efficacious as surgery for simple ruptured lumbar intervertebral disk disease. Whereas the complication rates of chemonucleolysis are probably no greater than that for surgery, the incidence of unpreventable anaphylaxis and other untoward reactions makes it certainly no more safe. There is no biological basis for the belief that chemonucleolysis will result in a shorter convalescence than surgery, and it appears that chemonucleolysis has significantly increased the cost of invasive treatment of patients with ruptured lumbar intervertebral disk disease.
    [Abstract] [Full Text] [Related] [New Search]